Document Detail

Use of digoxin in infants and children, with specific emphasis on dosage.
MedLine Citation:
PMID:  3012054     Owner:  NLM     Status:  MEDLINE    
The foregoing discussion leads to several general conclusions regarding the use of digoxin in the pediatric patient. First, pharmacokinetic studies indicate that somewhat higher doses are required in the infant to attain the same serum levels as in the adult. Important sources for this difference appear to be more rapid body clearance of digoxin and larger volume of distribution in the infant. Second, higher serum digoxin levels are not indicated on the basis of decreased myocardial uptake of digoxin in the infant. Tissue uptake of digoxin, as indicated by myocardium/serum digoxin ratios, is higher in infants and children than in adults. Third, according to results of animal studies, the inotropic sensitivity to digoxin in the young is probably greater--certainly not less--than in the adult. This is opposite to a commonly held view that the immature heart is less sensitive to cardiac glycosides and therefore requires higher serum levels for a therapeutic effect. Rather, the infant has decreased sensitivity of the conduction system to digitalis toxicity, and healthy myocardium less prone to arrhythmia than the adult. Therefore the infant may tolerate, but does not require, higher serum levels of digoxin. Fourth, high levels of serum digoxin (greater than 2 ng/ml) are not associated with greater inotropic effects in the pediatric patient. The higher dosages of digoxin are, instead, associated with greater frequency of toxic effects, especially in infants receiving concomitant diuretic therapy. Therefore, a digoxin dosage recommendation is presented, that will result in mean serum digoxin levels of 1.1 to 1.7 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
M K Park
Related Documents :
6159914 - The switch from haemoglobin f to a: the time course of qualitative and quantitative var...
7097424 - Jaundice meter: evaluation of new guidelines.
16205054 - The effectiveness of oral tin mesoporphyrin prophylaxis in reducing bilirubin productio...
6767824 - Prospective controlled study of parenteral nutrition-associated cholestatic jaundice: e...
25456574 - Observed transition from opioid analgesic deaths toward heroin.
17762204 - Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-isch...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of pediatrics     Volume:  108     ISSN:  0022-3476     ISO Abbreviation:  J. Pediatr.     Publication Date:  1986 Jun 
Date Detail:
Created Date:  1986-07-14     Completed Date:  1986-07-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0375410     Medline TA:  J Pediatr     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  871-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Digoxin / administration & dosage,  adverse effects,  metabolism*
Kidney / metabolism
Metabolic Clearance Rate
Myocardium / metabolism*
Sodium-Potassium-Exchanging ATPase / metabolism*
Reg. No./Substance:
20830-75-5/Digoxin; EC ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of vitamin E deficiency and non-biological antioxidant (DPPD) on the function of the pituita...
Next Document:  Neurologic complications in oral polio vaccine recipients.